ArticleFrontiers in oncology2025
Establishment and validation of a prognostic nomogram for extra-gastrointestinal stromal tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extra-gastrointestinal stromal tumor (EGIST) is a rare subtype of gastrointestinal stromal tumor, with limited information on its clinical characteristics and prognostic factors. This study aims to identify the risk factors affecting survival in EGIST patients and to develop a prognostic nomogram for predicting EGIST-specific survival (TSS). Methods: Patients diagnosed with EGIST, aged 18 to 80, were enrolled from the Surveillance, Epidemiology, and End Results (SEER) Research Plus database, covering the years 2000 to 2019. Univariate and multivariate analyses were conducted to identify risk factors for developing a nomogram. The predictive accuracy of the nomogram was evaluated using time-dependent receiver operating characteristic curves, calibration plots, and the concordance index. Decision curve analysis (DCA) was performed to assess the nomogram's clinical utility and net benefit for application in clinical practice. Additionally, the nomogram's performance was compared with the tumor SEER stage. Results: A total of 389 patients were included in this study. Univariate and multivariate analyses identified age, household income, surgery, tumor grade, tumor size, and tumor SEER stage as significant predictors of TSS (all P<0.05). These factors were incorporated into the prognostic nomogram. The nomogram demonstrated superior prognostic value compared to the tumor SEER stage alone, as evidenced by the area under the curve and concordance index. The calibration plot indicated a high level of accuracy in forecasting survival probabilities. Furthermore, DCA highlighted the nomogram's clinical applicability and positive net benefit. The nomogram also proved more effective than the tumor SEER stage alone in identifying patients with poorer prognoses. Conclusions: Age, household income, surgery, tumor grade, tumor size, and tumor SEER stage were identified as risk factors for TSS in patients with EGIST. We have developed and validated a prognostic nomogram to predict TSS in EGIST patients, which may improve patient management and guide personalized medical treatment for EGIST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.